Daily News Podcast

Esketamine gets the green light for depression

Publish date: March 7, 2019

 

The FDA approves intranasal esketamine for refractory major depressive disorder. A behavioral intervention improves physical activity in patients with diabetes. Groups of physicians produce more accurate diagnoses than individuals. And there’s a new target for reducing sodium consumption.
Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

Opioids often prescribed in low-income areas
MDedge Neurology
What I learned from Navy SEALs about resilience
MDedge Neurology
Mediterranean diet cut Parkinson’s risk
MDedge Neurology
500 Women in Medicine: Part II
MDedge Neurology
A prescription for medicine’s gender inequality
MDedge Neurology
Parental leave inequities: Kirti Magudia and Thomas Ng, Part I
MDedge Neurology
Trump targets abortion by denying family planning funds
MDedge Neurology
Online vitriol’s expansion into doctor discussion sites
MDedge Neurology
Will having fewer primary care physicians shorten Americans’ lifespans?
MDedge Neurology
Cancer-battling breath, Zombie Bambi, and hops as health food
MDedge Neurology